il s'agissait d'une éruption généralisée, dans un cas, l'éruption atteignait le décolleté et le visage avec un oedème (grade 2) Dans les 3 cas, il n'y avait pas de perturbation de bilan hépatorénal ,
Effets cutan??s des nouvelles mol??cules utilis??es en canc??rologie, La Revue de M??decine Interne, vol.30, issue.5, pp.401-410, 2009. ,
DOI : 10.1016/j.revmed.2009.02.001
Th??rapeutiques antiangiog??niques des??tumeurs solides, La Revue de M??decine Interne, vol.28, pp.7-8, 2007. ,
DOI : 10.1016/j.revmed.2007.03.021
Voies moléculaires de l'angiogenèse tumorale et nouvelles approches thérapeutiques ciblées dans le cancer du rein, Prog. Urol, vol.15, pp.1021-1029, 2005. ,
Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib, Oncology, vol.77, issue.5, pp.257-271, 2009. ,
DOI : 10.1159/000258880
The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review, European Journal of Cancer, vol.42, issue.18, pp.3127-3139, 2006. ,
DOI : 10.1016/j.ejca.2006.09.015
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature, American Journal of Physiology-Heart and Circulatory Physiology, vol.290, issue.2, pp.560-576, 2006. ,
DOI : 10.1016/S0002-9440(10)62567-9
Angiogen??se : l???exemple du cancer r??nal, Progr??s en Urologie, vol.18, pp.309-314, 2008. ,
DOI : 10.1016/S1166-7087(08)74559-7
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nature Reviews Drug Discovery, vol.47, issue.10, pp.835-844, 2006. ,
DOI : 10.4161/cc.3.2.648
Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli, Science, vol.301, issue.5629, pp.94-96, 2003. ,
DOI : 10.1126/science.1082015
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-134, 2007. ,
DOI : 10.1056/NEJMoa060655
Sorafenib in Advanced Hepatocellular Carcinoma, New England Journal of Medicine, vol.359, issue.4, pp.378-390, 2008. ,
DOI : 10.1056/NEJMoa0708857
Utilisation du soraf??nib (Nexavar??) dans le traitement du carcinome h??patocellulaire??: recommandations Prodige Afef, Gastroent??rologie Clinique et Biologique, vol.32, issue.1, pp.3-7, 2008. ,
DOI : 10.1016/j.gcb.2007.11.001
Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors, The Oncologist, vol.13, issue.8, pp.845-858, 2008. ,
DOI : 10.1634/theoncologist.2007-0233
Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial, European Journal of Cancer, vol.45, issue.4, pp.579-587, 2009. ,
DOI : 10.1016/j.ejca.2008.10.039
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis, British Journal of Cancer, vol.24, issue.16, pp.581-586, 2006. ,
DOI : 10.1038/sj.onc.1208841
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma, Journal of Clinical Oncology, vol.27, issue.17, pp.2823-2830, 2009. ,
DOI : 10.1200/JCO.2007.15.7636
Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group, Journal of Clinical Oncology, vol.26, issue.13, pp.2178-2185, 2008. ,
DOI : 10.1200/JCO.2007.14.8288
Angiogenesis, lymphangiogenesis and melanoma metastasis, Oncogene, vol.22, issue.20, pp.3172-3179, 2003. ,
DOI : 10.1073/pnas.93.25.14765
URL : http://www.nature.com/onc/journal/v22/n20/pdf/1206457a.pdf
Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.5, pp.1493-1499, 2009. ,
DOI : 10.1210/jc.2008-0923
VEGF Inhibitors and Prostate Cancer Therapy, Current Molecular Pharmacology, vol.2, issue.2, pp.161-168, 2009. ,
DOI : 10.2174/1874467210902020161
URL : http://europepmc.org/articles/pmc2711630?pdf=render
New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways, The Oncologist, vol.13, issue.3, pp.289-298, 2008. ,
DOI : 10.1634/theoncologist.2007-0134
Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer, The Oncologist, vol.12, issue.2, pp.191-200, 2007. ,
DOI : 10.1634/theoncologist.12-2-191
Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.27, issue.26, pp.4274-4280, 2009. ,
DOI : 10.1200/JCO.2009.22.0541
Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice, Neuroscience, vol.162, issue.4, pp.1220-1231, 2009. ,
DOI : 10.1016/j.neuroscience.2009.05.019
Effets secondaires cutan??s du sorafenib et du sunitinib, Annales de Dermatologie et de V??n??r??ologie, vol.135, issue.2, pp.148-153, 2008. ,
DOI : 10.1016/j.annder.2007.12.006
Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor, Archives of Dermatology, vol.144, issue.7, pp.886-892, 2008. ,
DOI : 10.1001/archderm.144.7.886
N??vus ??ruptifs sous soraf??nib, Annales de Dermatologie et de V??n??r??ologie, vol.135, issue.10, pp.672-674, 2008. ,
DOI : 10.1016/j.annder.2008.04.016
Sorafenibinduced eruptive melanocytic lesions, Arch Dermatol, vol.144, pp.820-822, 2008. ,
DOI : 10.1001/archderm.144.6.820
URL : http://europepmc.org/articles/pmc2556207?pdf=render
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor, Clinical and Experimental Dermatology, vol.31, issue.6, pp.783-785, 2006. ,
DOI : 10.1016/S0190-9622(99)70488-3
Keratoacanthomas associated with sorafenib??therapy, Journal of the American Academy of Dermatology, vol.56, issue.1, pp.171-172, 2007. ,
DOI : 10.1016/j.jaad.2006.10.032
URL : http://europepmc.org/articles/pmc1781060?pdf=render
Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib, Archives of Dermatology, vol.144, issue.6, pp.779-782, 2008. ,
DOI : 10.1001/archderm.144.6.779
Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib, Journal of Clinical Oncology, vol.27, issue.23, pp.59-61, 2009. ,
DOI : 10.1200/JCO.2009.23.4823
The histologic spectrum of epithelial neoplasms induced by sorafenib, Journal of the American Academy of Dermatology, vol.61, issue.3, pp.522-527, 2009. ,
DOI : 10.1016/j.jaad.2008.10.043
K??ratoacanthomes multiples ??ruptifs induits par le soraf??nib, Annales de Dermatologie et de V??n??r??ologie, vol.136, issue.12, pp.894-897, 2009. ,
DOI : 10.1016/j.annder.2009.09.010
Sorafenib-induced erythema multiforme, Journal of the American Academy of Dermatology, vol.56, issue.3, pp.527-528, 2007. ,
DOI : 10.1016/j.jaad.2006.10.981
Erythema multiforme induced by sorafenib, Clinical and Experimental Dermatology, vol.56, issue.7, pp.368-369, 2009. ,
DOI : 10.1111/j.1365-2230.2009.03320.x
Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma, Cutaneous and Ocular Toxicology, vol.28, issue.2, pp.90-92, 2009. ,
DOI : 10.1016/j.jaad.2006.10.981
Perforating folliculitis, angioedema, hand-foot syndrome ?????? multiple cutaneous side effects in a patient treated with sorafenib, Journal der Deutschen Dermatologischen Gesellschaft, vol.4, issue.3, pp.449-452, 2009. ,
DOI : 10.1111/j.1610-0387.2009.07017.x
Leukocytoclastic Vasculitis Masquerading as Hand-Foot Syndrome in a Patient Treated With Sorafenib, Archives of Dermatology, vol.142, issue.11, pp.1510-1511, 2006. ,
DOI : 10.1001/archderm.142.11.1510
Sorafenib: atypical cutaneous side effects, Eur J Dermatol, vol.17, pp.549-550, 2007. ,
Hyperkeratosis of nipple skin during sorafenib treatment, Digestive and Liver Disease, vol.41, issue.8, p.611, 2009. ,
DOI : 10.1016/j.dld.2009.02.001
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?, European Journal of Cancer, vol.42, issue.4, pp.548-556, 2006. ,
DOI : 10.1016/j.ejca.2005.11.014
Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib, The Oncologist, vol.15, issue.1, pp.85-92, 2010. ,
DOI : 10.1634/theoncologist.2009-0143
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib, British Journal of Dermatology, vol.347, issue.5, pp.1045-1051, 2009. ,
DOI : 10.1111/j.1365-2133.2009.09290.x
Subungual Splinter Hemorrhages: A Clinical Window to Inhibition of Vascular Endothelial Growth Factor Receptors?, Annals of Internal Medicine, vol.143, issue.4, pp.313-314, 2005. ,
DOI : 10.7326/0003-4819-143-4-200508160-00021
Cutaneous side-effects of kinase inhibitors and blocking antibodies, The Lancet Oncology, vol.6, issue.7, pp.491-500, 2005. ,
DOI : 10.1016/S1470-2045(05)70243-6
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer, Journal of Clinical Oncology, vol.24, issue.1, pp.25-35, 2006. ,
DOI : 10.1200/JCO.2005.02.2194
Clinical translation of angiogenesis inhibitors, Nature Reviews Cancer, vol.17, issue.10, pp.727-739, 2002. ,
DOI : 10.3109/08977199909103521
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.27, issue.22, pp.3584-3590, 2009. ,
DOI : 10.1200/JCO.2008.20.1293
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial, The Lancet, vol.368, issue.9544, pp.1329-1338, 2006. ,
DOI : 10.1016/S0140-6736(06)69446-4
Sunitinib, BioDrugs, vol.27, issue.2, pp.377-389, 2009. ,
DOI : 10.7326/0003-4819-145-9-200611070-00008
Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane, Journal of Clinical Oncology, vol.26, issue.11, pp.1810-1816, 2008. ,
DOI : 10.1200/JCO.2007.14.5375
Skin ulcers in Klippel???Trenaunay syndrome respond to sunitinib, Translational Research, vol.151, issue.4, pp.194-196, 2008. ,
DOI : 10.1016/j.trsl.2008.01.002
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy, Annals of Oncology, vol.25, issue.5, pp.319-324, 2010. ,
DOI : 10.1007/s10637-007-9050-y
URL : https://academic.oup.com/annonc/article-pdf/21/2/319/929873/mdp323.pdf
Phase II study of sunitinib in men with advanced prostate cancer, Annals of Oncology, vol.86, issue.3, pp.913-920, 2009. ,
DOI : 10.1210/jc.86.3.1341
Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate, Journal of Neuro-Oncology, vol.37, issue.2, pp.305-308, 2010. ,
DOI : 10.1007/s11060-009-0027-x
Biochemical and Pathological Response of Prostate Cancer in a Patient with Metastatic Renal Cell Carcinoma on Sunitinib Treatment, Japanese Journal of Clinical Oncology, vol.361, issue.20 May Suppl, pp.833-836, 2009. ,
DOI : 10.1016/S0140-6736(03)13554-4
A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184, Gynecologic Oncology, vol.116, issue.2, pp.163-167, 2010. ,
DOI : 10.1016/j.ygyno.2009.08.012
Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study, Gynecologic Oncology, vol.115, issue.3, pp.460-465, 2009. ,
DOI : 10.1016/j.ygyno.2009.09.011
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.115-124, 2007. ,
DOI : 10.1056/NEJMoa065044
Tyrosine kinase inhibition and grey hair, The Lancet, vol.361, issue.9362, p.1056, 2003. ,
DOI : 10.1016/S0140-6736(03)12805-X
Hand-Foot Syndrome and Seborrheic Dermatitis-Like Rash Induced by Sunitinib in a Patient With Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.24, issue.36, pp.5786-5788, 2006. ,
DOI : 10.1200/JCO.2006.08.6868
Scrotal cutaneous side effects of sunitinib, N. Engl. J. Med, vol.359, pp.975-976, 2008. ,
Syndrome pied-main n??crotique sous antiangiog??niques chez une patiente porteuse d???une acropathie ulc??romutilante de Th??venard, Journal des Maladies Vasculaires, vol.34, issue.3, pp.222-225, 2009. ,
DOI : 10.1016/j.jmv.2009.01.001
Toxic Dermatolysis, Tissue Necrosis and Impaired Wound Healing due to Sunitinib Treatment Leading to Forefoot Amputation, Urologia Internationalis, vol.82, issue.2, pp.246-248, 2009. ,
DOI : 10.1159/000200809
Successful Desensitization Protocol for Hypersensitivity Reaction Caused by Sunitinib in a Patient with a Gastrointestinal Stromal Tumor, Japanese Journal of Clinical Oncology, vol.97, issue.2, pp.163-165, 2010. ,
DOI : 10.1059/0003-4819-105-1-148
Les th??rapies cibl??es et leurs indications dans les tumeurs solides, La Revue de M??decine Interne, vol.30, issue.5, pp.416-424, 2009. ,
DOI : 10.1016/j.revmed.2008.12.022
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer, New England Journal of Medicine, vol.357, issue.26, pp.2666-2676, 2007. ,
DOI : 10.1056/NEJMoa072113
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response, Anti-Cancer Drugs, vol.17, issue.10, pp.1227-1229, 2006. ,
DOI : 10.1097/01.cad.0000231481.07654.fc
Bevacizumabinduced hand-foot syndrome: circumscribed type, Br. J. Dermatol, p.2010 ,
DOI : 10.1111/j.1365-2133.2010.09716.x
Chemotherapy-Induced Acral Erythema: A Clinical and Histopathologic Study of 44 Cases, Actas Dermo-Sifiliogr??ficas (English Edition), vol.99, issue.4 ,
DOI : 10.1016/S1578-2190(08)70252-X
Erythematous Eruption of the Palms and Soles Associated with Mitotane Therapy, Dermatology, vol.148, issue.2, pp.90-92, 1974. ,
DOI : 10.1159/000251603
Palmar???plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre, European Journal of Oncology Nursing, vol.11, issue.3, pp.238-246, 2007. ,
DOI : 10.1016/j.ejon.2006.10.004
The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy, Eur J Dermatol, vol.16, pp.494-499, 2006. ,
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda??), European Journal of Oncology Nursing, vol.8, issue.1, pp.31-40, 2004. ,
DOI : 10.1016/j.ejon.2004.06.007
Palmar-plantar erythrodysesthesia, Clin J Oncol Nurs, vol.9, pp.103-106, 2005. ,
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome), Annals of Oncology, vol.67, issue.6 ,
DOI : 10.1093/annonc/mdl079
URL : https://academic.oup.com/annonc/article-pdf/18/7/1159/639500/mdl477.pdf
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity, Oncology, vol.16, pp.31-37, 2002. ,
High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy, Annals of Oncology, vol.14, issue.11, pp.1691-1692, 2003. ,
DOI : 10.1093/annonc/mdg446
Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?, Annals of Oncology, vol.16, issue.7, pp.1210-1211, 2005. ,
DOI : 10.1002/lapl.200310028
Chemotherapy-induced acral erythema: report of a case and immunohistochemical findings. Clinical dermatology . Concise report, Clinical and Experimental Dermatology, vol.10, issue.5, pp.386-388, 2000. ,
DOI : 10.1001/archderm.122.9.1023
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma, Cancer, vol.13, issue.5, pp.1037-1047, 2000. ,
DOI : 10.1200/JCO.1995.13.4.996
The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma1, Gynecologic Oncology, vol.93, issue.2, pp.513-516, 2004. ,
DOI : 10.1016/j.ygyno.2004.02.019
Prevention strategies in palmar???plantar erythrodysesthesia onset: The role of regional cooling, Gynecologic Oncology, vol.108, issue.2, pp.332-335, 2008. ,
DOI : 10.1016/j.ygyno.2007.10.021
Current Canadian Experience With Capecitabine, Cancer Nursing, vol.26, issue.2, pp.161-167, 2003. ,
DOI : 10.1097/00002820-200304000-00011
Topical henna for capecitabine induced hand???foot syndrome, Investigational New Drugs, vol.51, issue.2, pp.189-192, 2008. ,
DOI : 10.1515/znc-2004-7-803
Impact of prophylactic pyridoxine on occurrence of hand???foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer, Breast Cancer, vol.55, issue.4, p.2009 ,
DOI : 10.1007/BF00216925
Treatment of cytarabine acral erythema with corticosteroids, Journal of the American Academy of Dermatology, vol.24, issue.6, pp.1023-1025, 1991. ,
DOI : 10.1016/S0190-9622(08)80126-0
Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model, Clin. Cancer Res, vol.4, pp.1567-1571, 1998. ,
Methotrexate-induced bullous acral erythema in a child, Journal of the American Academy of Dermatology, vol.52, issue.5, pp.93-95, 2005. ,
DOI : 10.1016/j.jaad.2004.11.065
Oral dexamethasone attenuates Doxil??-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies, Gynecologic Oncology, vol.94, issue.2, pp.320-324, 2004. ,
DOI : 10.1016/j.ygyno.2004.05.027
Palmar-plantar erythrodysesthesia due to docetaxelcapecitabine therapy is treated with vitamin E without dose reduction, Breast, vol.15, pp.414-424, 2006. ,
DOI : 10.1016/j.breast.2005.07.007
5-Fluorouracil Dermatitis Prophylaxis with a Nicotine Patch, Annals of Internal Medicine, vol.120, issue.9, p.813, 1994. ,
DOI : 10.7326/0003-4819-120-9-199405010-00025
has-sante.fr. XELODA. Site consulté le 10 mars, 2009. ,
Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib, The Oncologist, vol.13, issue.9, pp.1001-1011, 2008. ,
DOI : 10.1634/theoncologist.2008-0131
Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis, Acta Oncologica, vol.13, issue.2, pp.176-186, 2008. ,
DOI : 10.1158/1078-0432.CCR-06-2328
Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non???Renal Cell Carcinoma: A Meta-analysis, Clinical Genitourinary Cancer, vol.7, issue.1, pp.11-19, 2009. ,
DOI : 10.3816/CGC.2009.n.002
Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand?foot syndrome?, Clinical and Experimental Dermatology, vol.73, issue.5, pp.519-521, 2007. ,
DOI : 10.1016/S0190-9622(00)90112-9
Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib : Impact on quality of life (QoL), J Clin Oncol, vol.26, 2008. ,
Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy, Clinical Cancer Research, vol.15, issue.4, pp.1411-1416, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-1141
Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment, Clinical Cancer Research, vol.15, issue.24, p.7749, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1190
URL : http://clincancerres.aacrjournals.org/content/clincanres/15/24/7749.1.full.pdf
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy, British Journal of Dermatology, vol.24, issue.3, pp.592-596, 2008. ,
DOI : 10.1111/j.1365-2133.2007.08357.x
Hand-Foot and Stump Syndrome to Sorafenib, Journal of Clinical Oncology, vol.25, issue.3, pp.341-343, 2007. ,
DOI : 10.1200/JCO.2006.08.9565
Lack of Association Between Excretion of Sorafenib in Sweat and Hand-Foot Skin Reaction, Pharmacotherapy, vol.30, issue.1, pp.52-56, 2010. ,
DOI : 10.1111/j.1365-2133.2007.08357.x
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?, Targeted Oncology, vol.1, issue.4, pp.307-310, 2009. ,
DOI : 10.1093/annonc/mdn389
Blackberry-induced hand-foot skin reaction to sunitinib, Investigational New Drugs, vol.143, issue.4, pp.389-390, 2009. ,
DOI : 10.7326/0003-4819-143-4-200508160-00021
Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma, Japanese Journal of Clinical Oncology, vol.37, issue.10, pp.755-762, 2007. ,
DOI : 10.1093/jjco/hym095
Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity, Journal of Clinical Oncology, vol.27, issue.26, pp.4406-4412, 2009. ,
DOI : 10.1200/JCO.2008.21.7679
Localized Palmar Plantar Epidermal Hyperplasia: A Previously Undefined Dermatologic Toxicity to Sorafenib, The Oncologist, vol.12, issue.10, pp.1178-1182, 2007. ,
DOI : 10.1634/theoncologist.12-10-1178
URL : http://theoncologist.alphamedpress.org/content/12/10/1178.full.pdf
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib, Annals of Oncology, vol.11, issue.5, pp.1955-1961, 2008. ,
DOI : 10.1188/07.CJON.649-656
Bioth??rapies cibl??es en canc??rologie digestive??: prise en charge de leurs effets secondaires, Gastroent??rologie Clinique et Biologique, vol.33, issue.4, pp.306-322, 2009. ,
DOI : 10.1016/j.gcb.2009.02.008
Successful Topical Treatment of Sorafenib-Induced Hand-Foot Skin Reaction in a Child with Hepatocellular Carcinoma, Pediatric Dermatology, vol.47, issue.3, pp.349-350, 2009. ,
DOI : 10.1111/j.1525-1470.2009.00933.x
Hand-foot syndrome with docetaxel : A five-case series, Annals of Saudi Medicine, vol.28, issue.5, pp.374-377, 2008. ,
DOI : 10.4103/0256-4947.51691
La relation médecin-malade en dermatologie, Ann Dermatol Venereol, vol.124, pp.864-868, 1997. ,
Patients' demands for prescriptions in primary care, BMJ, vol.310, issue.6987, pp.1084-1085, 1995. ,
DOI : 10.1136/bmj.310.6987.1084
L?????ducation th??rapeutique : un enjeu majeur en dermatologie, Annales de Dermatologie et de V??n??r??ologie, vol.132, issue.2, pp.111-113, 2005. ,
DOI : 10.1016/S0151-9638(05)79219-X
Education et dermatite atopique. L'expérience de l'unité de dermatologie pédiatrique du CHU de Bordeaux, Ann Dermatol Venereol, vol.130, pp.285-289, 2003. ,
Ulc??rations des membres inf??rieurs sous sunitinib, Annales de Dermatologie et de V??n??r??ologie, vol.137, issue.10, p.2010 ,
DOI : 10.1016/j.annder.2010.04.022
Wound healing process of a full-thickness skin wound model in rats, Int Surg, vol.92, issue.2, pp.63-72, 2007. ,
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents, Journal of Clinical Oncology, vol.27, issue.29, pp.4865-4873, 2009. ,
DOI : 10.1200/JCO.2009.22.3875